Skip to content

Frontlight ResearchEarly access

Institution

Hospital de Sant Pau

Barcelona, SpainWebsite

Also known as: Hospital de la Santa Creu i Sant Pau · Hospital of the Holy Cross and Saint Paul · HSCSP

536running trials
306closed trials
28,896publications (OpenAlex)

Running trials

Not yet recruiting
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source
Not yet recruiting
A study to learn how dapirolizumab pegol transfers to babies from pregnant mothers with active systemic lupus erythematosus
2025-524595-37-00· Phase 1· UCB Biopharma· Source
Not yet recruiting
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015· Phase 3· Boehringer Ingelheim· Source
Recruiting
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
NCT07781657· Phase 2· Hoffmann-La Roche· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source
Not yet recruiting
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Not yet recruiting
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Not yet recruiting
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· Phase 3· Almirall, S.A.· Source
Not yet recruiting
A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)
2025-522648-42-01· Phase 2/3· Crinetics Pharmaceuticals Inc.· Source
Recruiting
Evaluation of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
2025-523288-39-00· Phase 2· Mediar Therapeutics Inc.· Source
Recruiting
Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression
2025-524641-27-00· Phase 3· K-Group Beta Inc.· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· Phase 3· Hoffmann-La Roche· Source
Recruiting
A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2- NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
2026-525328-10-00· Phase 2· Medica Scientia Innovation Research S.L.· Source
Recruiting
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
2026-526654-14-01· Phase 3· Janssen Cilag International· Source
Recruiting
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial
2025-521209-42-00· Phase 4· Fondazione GONO G.I.· Source
Recruiting
Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
2026-525489-23-00· Phase 3· Amgen Inc.· Source
Recruiting
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07465289· Phase 3· UCB Biopharma SRL· Source
Not yet recruiting
Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)
NCT07247786· Phase 2· Fundación GECP· Source
Recruiting
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
NCT07711002· Phase 3· AstraZeneca· Source
Not yet recruiting
A phase II clinical trial of inotuzumab ozogamicin as prophylaxis for relapse in patients with lymphoblastic leukaemia after allogeneic stem cell haemotopoietic transplantation
2026-525964-17-00· Phase 2· Fundacion PETHEMA· Source
Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764· Phase 2· Bristol-Myers Squibb· Source
Recruiting
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
NCT07665450· Phase 3· Janssen Research & Development, LLC· Source
Not yet recruiting
A study to learn about the effects of Trontinemab in participants at risk for Alzheimer‘s disease
2025-524314-29-00· Phase 3· F. Hoffmann-La Roche AG· Source
Not yet recruiting
Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer
NCT07717099· Phase 2· Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD· Source
Not yet recruiting
iSGLT2 in permanent atrial fibrillation, heart failure with preserved ejection fraction and intermediate NT-proBNP values: randomized clinical trial
2026-525968-18-00· Phase 4· Institut D Investigacio Sanitaria Pere Virgili· Source
Not yet recruiting
Multicentre, randomized, open label study comparing the concomitant administration of trabectedin and low-dose radiotherapy versus trabectedin alone in patients with advanced sarcoma
2026-525703-27-00· Phase 4· Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz· Source
Not yet recruiting
Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Beneﬁted from Continued Treatment.
2026-526419-13-00· Phase 3· AstraZeneca AB· Source
Recruiting
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
2025-524793-42-00· Phase 2· Janssen Cilag International· Source
Recruiting
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
NCT07737743· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.
NCT07460986· Phase 1/2· MedSIR· Source
Recruiting
ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
NCT06716021· Phase 3· Milestone Pharmaceuticals Inc.· Source
Recruiting
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
NCT07636811· Phase 2· Alnylam Pharmaceuticals· Source
Not yet recruiting
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.
2026-525883-17-00· Phase 3· Genmab A/S· Source
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300· Phase 3· Eli Lilly and Company· Source
Recruiting
A trial to learn how safe elecoglipron is and how well it works in adults living with obesity or excess body weight with or without type 2 diabetes
2025-524688-19-00· Phase 3· AstraZeneca AB· Source
Recruiting
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644· Phase 3· SystImmune Inc.· Source
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782· Phase 2· Verastem, Inc.· Source
Recruiting
A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflammation in adult participants with moderately to severely active rheumatoid arthritis.
2025-522076-85-00· Phase 2· AstraZeneca AB· Source
Recruiting
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
NCT07621809· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
NCT07673627· Phase 2· argenx· Source
Recruiting
Spanish Prospective Registry of Hydra THV for Transcatheter Aortic Valve Implantation
NCT07566624· Fundación EPIC· Source
Recruiting
Pridopidine Phase 3 Study in Huntington's Disease
NCT07609108· Phase 3· Prilenia· Source
Not yet recruiting
Evaluation of Calcified Coronary Lesion Preparation With the Naviscore Scoring Balloon
NCT07650578· University of Mons· Source
Not yet recruiting
Optimizing the Use of Aspirin for the Prevention of Preeclampsia
NCT07665853· Phase 3· Hospital Universitari Vall d'Hebron Research Institute· Source
Recruiting
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
NCT07589634· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
2025-522818-23-00· Phase 3· Zai Lab (US) LLC· Source
Recruiting
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916· Phase 3· ViiV Healthcare· Source
Active, not recruiting
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.
2023-503298-39-00· Phase 3· AstraZeneca AB· Source

Showing 50 of 536.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Completed
Clinical trial in multiple hospitals to explore new ways to diagnose and monitor tuberculosis treatment
2025-522235-34-00· Phase 4· Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz· Source
Active, not recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
NCT07234942· Phase 1· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease
NCT07246941· Phase 1· Hoffmann-La Roche· Source
Completed
C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People With Relapsed or Refractory Diffuse Large B Cell Lymphoma
NCT05896163· Phase 1/2· Pfizer Inc.· Source
Completed
Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP
2024-515386-34-00· Phase 2· Nuvig Therapeutics Inc.· Source
Completed
Dose-ranging study evaluating the efficacy and safety of EVO756 in adults with Chronic Spontaneous Urticaria.
2024-518786-10-01· Phase 2· Evommune Inc.· Source
Completed
A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinophilic asthma
2024-515162-13-00· Phase 3· AstraZeneca AB· Source
Completed
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia
2024-515539-31-00· Phase 2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265· Phase 3· Immutep S.A.S.· Source
Completed
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures
2024-517061-16-01· Phase 2· Praxis Precision Medicines Inc.· Source
Completed
A RANDOMIZED PHASE I, DOUBLE-BLIND, PARALLEL, COMPARATIVE ASSESSMENT OF PHARMACOKINETICS, SAFETY, PHARMACODYNAMICS, AND IMMUNOGENICITY OF LT-01 (AN OMALIZUMAB BIOSIMILAR CANDIDATE [TEST]) LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION VERSUS EU-APPROVED XOLAIR® LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION (REFERENCE) IN HEALTHY SUBJETCS: CIMA STUDY.
2023-505908-28-00· Phase 1· Laboratorios Liomont S.A. de C.V.· Source
Completed
A study to compare effects and safety of CT-P51 and Keytruda in patients with previously untreated metastatic lung cancer
2024-514048-98-00· Phase 3· Celltrion Inc.· Source
Active, not recruiting
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
NCT06219317· Phase 2· European Organisation for Research and Treatment of Cancer - EORTC· Source
Active, not recruiting
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522· Phase 2· Amgen· Source
Terminated
Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)
NCT06673069· Phase 1· Ionis Pharmaceuticals, Inc.· Source
Completed
Study to evaluate food effect on the pharmacokinetics of mesalazine oral formulation in healthy volunteers.
2024-514748-10-00· Phase 1· Faes Farma S.A.· Source
Completed
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1)
2024-514559-13-00· Phase 2/3· Praxis Precision Medicines Inc.· Source
Completed
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open- labeled Long-term Extension Treatment with Aticaprant
2024-511557-21-00· Phase 3· Janssen Cilag International· Source
Completed
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjögren’s Disease
2024-512986-15-00· Phase 2· Kiniksa Pharmaceuticals GmbH· Source
Completed
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa
2024-511363-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027· Phase 3· Cerevance· Source
Active, not recruiting
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
NCT06315751· Phase 2· Noema Pharma AG· Source
Completed
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
NCT06667414· Hoffmann-La Roche· Source
Completed
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
NCT06588738· Phase 3· Alumis Inc· Source
Completed
Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )
NCT06341712· Phase 2· Ipsen Innovation· Source
Active, not recruiting
Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
NCT06359002· Phase 1· Byondis B.V.· Source
Active, not recruiting
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
NCT06471829· Phase 2· H. Lundbeck A/S· Source
Completed
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy
2023-506696-10-00· Phase 3· F. Hoffmann-La Roche AG· Source
Completed
A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoriasis
2023-508992-35-00· Phase 2· Janssen Cilag International· Source
Completed
Compression Therapy of the Lower Limbs in Patients With Decompensated Heart Failure
NCT06418932· Fundación para la Investigación del Hospital Clínico de Valencia· Source
Completed
A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.
2023-506881-30-00· Phase 1· H e x a l AG· Source
Terminated
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
NCT06241573· Phase 2/3· Boehringer Ingelheim· Source
Completed
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817· Phase 3· Incyte Corporation· Source
Completed
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
NCT05813288· Phase 3· Areteia Therapeutics Inc.· Source
Completed
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
NCT06119217· Phase 2· Trishula Therapeutics, Inc.· Source
Completed
A clinical study for patients with newly diagnosed, locally advanced non-small cell lung cancer (NSCLC) with a change in the ALK-gene, to test the effect of brigatinib after standard chemotherapy and radiation therapy is completed.
NCT05718297· Phase 2· ETOP IBCSG Partners Foundation· Source
Completed
A study to investigate the effect of different doses of AZD0780 on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo and its safety and tolerability in participants 18 to 75 years of age with dyslipidemia
2023-506197-12-00· Phase 2· Astrazeneca AB· Source
Completed
VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
NCT06214052· Phase 2· ViiV Healthcare· Source
Completed
A phase IIa, open label, single centre study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of orally dosed MBF-015 in Huntington's disease patients
2023-505241-10-00· Phase 2· Medibiofarma S.L.· Source
Terminated
Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
NCT06268574· Phase 2· Ryvu Therapeutics SA· Source
Completed
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)
2023-505910-10-00· Phase 2· Ryvu Therapeutics S.A.· Source
Completed
Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction treatment in BRAF (V600E) mutated MSS, initially resectable or potentially resectable advanced colorectal cancer: CEBBRA study.
2022-502413-29-00· Phase 2· Asociacion Grupo Tratamiento De Tumores Digestivos· Source
Completed
RANDOMIZED, CONTROLLED, OPEN, MULTICENTRIC CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION OF ANTI-TUBERCULOUS DRUGS BASED ON HIGH DOSE RIFAMPICIN, HIGH DOSE MOXIFLOXACIN AND LINEZOLID IN PATIENTS WITH BACILLIFEROUS PULMONARY TUBERCULOSIS (RML-TB).
2023-509075-17-00· Phase 2· Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca· Source
Active, not recruiting
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632· Phase 2· Pfizer· Source
Completed
A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma.
NCT04718675· Phase 1· Kronos Bio Inc.· Source
Terminated
IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
NCT06139328· Phase 2· Boehringer Ingelheim· Source
Completed
GRemubamab ErAdication Trial (GREAT-2)
2022-502494-41-00· Phase 2· NHS Tayside· Source
Completed
CHemical OptImization of Cerebral Embolectomy 2 (CHOICE 2).
NCT05797792· Phase 3· Hospital Clinic of Barcelona· Source
Completed
CHemical OptImization of Cerebral Embolectomy in patients with acute stroke treated with mechanical thrombectomy 2 (CHOICE2TRIAL)
2023-504262-32-01· Phase 3· Foundation Clinic For Biomedical Research· Source
Terminated
IMM60 and Pembrolizumab in Melanoma and NSCLC
NCT05709821· Phase 1/2· iOx Therapeutics· Source

Showing 50 of 306.

Registry name variants (54)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Hospital de la Santa Creu i Sant Pau
Barcelona, 08025
781 trials
Hospital Santa Creu i Sant Pau
Barcelona, 08025
16 trials
Hosp. de La Santa Creu I Sant Pau
Barcelona, 08025
9 trials
Hospital de Sant Pau
Barcelona, Barcelona 08041
5 trials
Hospital de la Santa Creu i de Sant Pau
Barcelona, 08025
4 trials
Hospital Sant Pau
Barcelona, 08041
4 trials
Hospital de Santa Creu I Sant Pau
Barcelona, 08025
3 trials
- NCT05758909Evaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation
- NCT05599061Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial
- NCT05192616Safety and Effectiveness Evaluation of iCover Covered Stent for the Treatment of the Aorto-iliac Occlusive Disease
Hospital de la Santa Creu i Sant Pau - Dept of Oncology
Barcelona
2 trials
- NCT05327530A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
- NCT03815643Avelumab Program Rollover Study
7240050 - Hospital de la Santa Creu i Sant Pau
Barcelona, 08025
1 trial
- NCT03473223Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
Dept of Endocrinology, Hospital Sant Pau
Barcelona
1 trial
- NCT03211624Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome
Hopital Sant Pau
Barcelona, 08036
1 trial
- NCT04809467A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
Hospital de la Santa Creu i Sant Pau Barcelona
Barcelona, 08026
1 trial
- NCT04083339Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona 08041
Barcelona, Barcelona 08025
1 trial
- NCT07461805Characterization of Type 1 Diabetes Subgroup: An Artificial Intelligence Analysis of Clinical and Glucometric Features
  Contact: Rosa Corcoy, MD PhD
HOSPITAL DE LA SANTA CREU I SANT PAU - Servicio de Hematología
Barcelona, 8025
1 trial
- NCT06284122Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Hospital de la Santa Creu i Sant Pau, Unidad de trastornos del movimiento
Barcelona
1 trial
- NCT07461220Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy
  Contact: PI Dr. Javier Pagonabarraga Mora
Hospital del la Santa Creu i Sant Pau
Barcelona, 08025
1 trial
- NCT04778397Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
Hospital de Sant Pau i de la Santa Creu
Barcelona, Catalonia 08041
1 trial
- NCT06653192EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction (CARPEDIEM Trial)
Hospital De Sant Pau I La Santa Creu
Barcelona
1 trial
- NCT03603184Atezolizumab Trial in Endometrial Cancer - AtTEnd
Hospital Santa Creu i Sant Pau /ID# 1142-0535
Barcelona, 08041
1 trial
- NCT02910583Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
Hospital Santa Creu i Sant Pau /ID# 124963
Barcelona, 08041
1 trial
- NCT02163694A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Hospital Santa Creu i Sant Pau /ID# 154125
Barcelona, 08041
1 trial
- NCT03047395A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
Hospital Santa Creu i Sant Pau /ID# 215429
Barcelona, 08041
1 trial
- NCT04379050Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
Hospital Santa Creu i Sant Pau /ID# 231821
Barcelona, 08041
1 trial
- NCT04497597A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Hospital Santa Creu i Sant Pau /ID# 238501
Barcelona, 08041
1 trial
- NCT04454658Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
Hospital Santa Creu i Sant Pau /ID# 240529
Barcelona, 08041
1 trial
- NCT05139602A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy
Hospital Santa Creu i Sant Pau /ID# 248511
Barcelona, 08041
1 trial
- NCT05081557A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
Hospital Santa Creu i Sant Pau /ID# 257294
Barcelona, 08041
1 trial
- NCT05599984Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
Hospital Santa Creu i Sant Pau /ID# 276319
Barcelona, 08041
1 trial
- NCT07284342A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa
  Contact: AbbVie Spain
Hospital Santa Creu i Sant Pau (Site 0241)
Barcelona, 08025
1 trial
- NCT03829319Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
Hospital Santa Creu i Sant Pau (Site 1501)
Barcelona, 08041
1 trial
- NCT04586231A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Neurology (Memory Unit) - Hospital de la Santa Creu i Sant Pau
Barcelona, 08025
1 trial
- NCT04498650A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD
Santa Creu i Sant Pau Hospital
Barcelona, 08025
1 trial
- NCT06127901Prevalence and Risk Factors for Postoperative Delirium 48 Hours After Surgery
Hospital de La Santa Creu i Sant Pau - Dermatologia
Barcelona, 08041
Hospital de la Santa Creu i Sant Pau /ID# 279642
Barcelona, 08041
Hospital de la Santa Creu i Sant Pau - Neurología
Barcelona
Hospital de la Santa Creu i Sant Pau Servicio de Dermatologia
Barcelona, 08041
Hospital de la Santa Creu i Sant Pau (Site 0385)
Barcelona, 08025
Hospital de la Santa Creu I Sant Pau Site #1304
Barcelona, 08041
Hospital de la Santa Creu i Sant Pau (Site 1807)
Barcelona, 08026
Hospital de la Santa Creu i Sant Pau, Unitat de Diabetis, Servei d'Endocrinologia i Nutrició, Universitat Autònoma de Barcelona
Barcelona, 8025
Hospital Santa Creu i Sant Pau /ID# 153193
Barcelona, 08041
Hospital Santa Creu i Sant Pau /ID# 201325
Barcelona, 08041
Hospital Santa Creu i Sant Pau /ID# 214714
Barcelona, 08041
Hospital Santa Creu i Sant Pau /ID# 225813
Barcelona, Barcelona 08041
Hospital Santa Creu i Sant Pau /ID# 229859
Barcelona, 08041
Hospital Santa Creu i Sant Pau /ID# 253869
Barcelona, 08041
Hospital Santa Creu i Sant Pau /ID# 257034
Barcelona, 08041
Hospital Santa Creu i Sant Pau /ID# 260498
Barcelona, 08041
Hospital Santa Creu i Sant Pau /ID# 262637
Barcelona, 08041
Hospital Santa Creu i Sant Pau /ID# 271311
Barcelona, 08041
Hospital Santa Creu i Sant Pau (Site 4102)
Barcelona, 08041
Hospital Sant Pau Barcelona
Barcelona, 08041
Hospital Sant Pau i la Santa Creu (Site 0905)
Barcelona, 08041
Sant Pau Hospital
Barcelona, 08040

Conditions

Diseases this institution publishes on or runs trials for.

Institution data: ROR 059n1d175 (CC0-1.0)Updated 14 Nov 2026

Report an error

Hospital de Sant Pau: trials and research groups – Frontlight Research